logo
  

Novavax Says One Mln Doses Of Nuvaxovid Ready For Use In UK To Fight Covid-19

Novavax, Inc. (NVAX), a vaccine maker focused on serious infectious diseases, said on Tuesday that an initial one million doses of Nuvaxovid or NVX-CoV2373 Covid-19 vaccine are now ready for use in the UK.

The MHRA has already granted conditional marketing authorization (CMA) for Nuvaxovid's use as a two-dose primary series vaccine for active immunization to prevent Covid-19. It will be offered per the Joint Committee on Vaccination and Immunisation (JCVI) advice.

Stanley Erck, CEO of Novavax, said: "With UK data showing that people infected with both Covid-19 and the flu are more than five times as likely to die compared to someone with no infection, it is more important than ever to consider any vaccine offered to you by the National Health Service."

The drug maker has also said that it has submitted a request to the MHRA for expanded CMA of Nuvaxovid as a booster in adults aged over 18. The decision on the request is still awaited.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Consumer Product Safety Commission or CPSC announced recall of thousands of children's Robes made in China and sold exclusively on Amazon.com by various companies. The recalled robes fail to meet the federal flammability standards for children's sleepwear, posing a risk of burn injuries to children. Further, citing the same concerns, Paper Cape children's pajamas manufactured in Peru ... Health services company Cigna Corp. reported Friday higher profit in its fourth quarter reflecting growth in both Evernorth and Cigna Healthcare segments. Adjusted earnings and topline beat market estimates. Looking ahead for fiscal 2023, the company projects adjusted earnings and adjusted revenues to be higher than last year, but below market view. French drug major Sanofi SA reported Friday higher profit in its fourth quarter with strong revenue growth mainly with strong sales of Dupixent. Looking ahead for fiscal 2023, the company projects higher business earnings, but the expected growth is slower than recorded in fiscal 2022. Sanofi shares were losing around 4 percent in the morning trading in Paris as well as in pre-market activity...
Follow RTT